respiratori
infect
respons
larg
global
burden
diseas
lower
respiratori
tract
infect
account
disabilityadjust
life
year
dali
worldwid
year
estim
million
pneumonia
episod
million
death
death
children
age
vast
major
case
mortal
occur
southeast
asia
tuberculosi
also
repres
substanti
challeng
global
health
account
allcaus
dali
lost
estim
million
death
control
effort
hamper
limit
vaccin
effect
coinfect
hiv
insuffici
diagnost
capac
lowincom
set
prolong
treatment
cours
emerg
drugresist
global
estim
death
annual
attribut
viral
reassort
lead
novel
strain
pandem
potenti
strain
emerg
mexico
rapidli
spread
worldwid
strain
remain
domin
influenza
strain
across
europ
emerg
strain
provid
caus
immedi
sever
acut
respiratori
syndrom
sar
aros
china
rapidli
caus
case
case
fatal
rate
almost
emerg
middl
east
respiratori
syndrom
coronaviru
caus
global
respiratori
syncyti
viru
rsv
estim
caus
year
million
new
episod
acut
lower
respiratori
tract
infect
worldwid
children
younger
year
estim
death
per
lowincom
variabl
coverag
measl
mump
rubella
vaccin
well
measl
still
respons
consider
diseas
burden
global
million
dali
pertussi
receiv
media
coverag
highincom
respiratori
infect
elsewher
implic
aetiolog
chronic
respiratori
diseas
chronic
obstruct
pulmonari
cystic
well
act
trigger
acut
cardiovascular
uk
institut
receiv
estim
billion
public
charit
fund
carri
infecti
diseas
research
accord
estim
polici
cure
uk
rank
second
global
term
amount
research
develop
r
fund
infecti
diseas
fund
cover
type
scienc
along
r
valu
chain
preclin
oper
implement
research
report
fund
respiratori
infectionrel
research
award
uk
institut
identifi
area
research
strength
possibl
invest
gap
relat
respiratori
global
health
relev
policymak
funder
research
briefli
discuss
new
approach
might
help
alloc
exist
resourc
identifi
new
sourc
invest
analys
studi
fund
period
inclus
identifi
relev
respiratori
infecti
diseas
global
health
studi
defin
investig
diseas
endem
uk
studi
clear
refer
anoth
countri
eg
tuberculosi
south
africa
pneumonia
categori
includ
preclin
studi
streptococcu
pneumonia
haemophilu
influenza
exclud
openaccess
data
pharmaceut
industri
limit
repres
method
describ
detail
overarch
dataset
construct
approach
major
sourc
public
charit
fund
infecti
diseas
research
studi
includ
wellcom
trust
medic
research
council
research
council
uk
govern
depart
european
commiss
bill
melinda
gate
foundat
research
chariti
figur
feasibl
fund
decis
list
websit
search
infecti
diseas
research
award
eg
wellcom
trust
otherwis
funder
directli
approach
ask
provid
inform
infectionrel
award
databas
also
search
includ
clinicaltrialsgov
nation
research
regist
studi
screen
relev
infecti
diseas
research
assign
mani
primari
diseas
categori
within
categori
topicspecif
subsect
includ
specif
pathogen
diseas
document
studi
also
alloc
one
four
categori
along
r
valu
chain
preclin
phase
product
develop
implement
oper
funder
either
consid
right
group
categori
inhous
univers
fund
research
chariti
govern
depart
total
funder
categori
categoris
carri
author
mgh
provision
dataset
circul
author
review
comment
jrf
mkc
fbw
verifi
random
sampl
dataset
author
agreement
measur
score
differ
settl
consensu
exclud
studi
immedi
relev
infect
veterinari
infecti
diseas
research
studi
unless
clear
zoonot
compon
studi
uk
collabor
fund
award
nonuk
institut
unfund
studi
also
exclud
grant
award
currenc
pound
sterl
convert
uk
pound
use
mean
exchang
rate
year
award
award
adjust
inflat
report
uk
pound
rel
level
invest
present
via
per
dali
figur
repres
total
invest
research
per
one
dali
dali
figur
extract
global
burden
diseas
use
fold
differ
statist
test
nonparametr
mannwhitney
rank
sum
test
ksampl
test
nonparametr
wilcoxon
signedrank
test
compar
total
invest
number
studi
mean
grant
median
grant
accord
specif
infect
diseas
system
fund
organis
crosscut
categori
associ
diseas
burden
research
invest
assess
use
spearman
rank
correl
coeffici
r
valu
greater
equal
consid
strongli
correl
greater
equal
less
consid
moder
correl
valu
equal
consid
poorli
correl
data
manag
carri
microsoft
excel
access
version
statist
analysi
stata
total
studi
screen
identifi
studi
met
inclus
criteria
total
invest
billion
studi
identifi
relev
respiratori
infect
research
total
fund
million
mean
studi
fund
sd
median
fund
iqr
preclin
scienc
receiv
million
total
respiratori
fund
across
studi
phase
trial
million
across
studi
product
develop
research
million
across
studi
implement
oper
research
million
across
studi
see
onlin
supplementari
data
clear
tempor
trend
fund
award
figur
global
healthrel
studi
receiv
million
across
studi
across
infecti
diseas
studi
clear
global
health
compon
repres
fund
diseas
tabl
tuberculosi
receiv
million
across
studi
influenza
million
across
studi
pneumonia
million
across
studi
preclin
scienc
receiv
invest
diseas
area
tuberculosi
influenza
pneumonia
see
onlin
supplementari
data
respiratori
diseas
receiv
substanti
less
fund
invest
heavili
concentr
within
preclin
exampl
rsv
total
million
preclin
pseudomona
research
total
million
preclin
sum
coronaviru
research
cover
six
studi
preclin
research
relat
infect
chronic
respiratori
diseas
mostli
cystic
fibrosi
chronic
obstruct
pulmonari
disord
asthma
total
million
across
studi
tabl
provid
breakdown
fund
select
disciplin
import
report
specif
respiratori
infecti
diseas
vaccinerel
studi
receiv
million
across
studi
million
tuberculosi
million
influenza
vaccin
research
therapeuticsrel
research
receiv
million
million
tuberculosi
million
influenza
research
diagnosticsrel
research
receiv
million
million
tuberculosi
million
influenza
diagnost
furthermor
studi
total
million
antimicrobi
resist
studi
total
million
primari
care
research
studi
total
million
relat
paediatr
health
econom
costeffect
studi
receiv
fund
million
funder
wellcom
trust
invest
greatest
amount
respiratori
infect
research
million
follow
medic
research
council
million
wellcom
trust
provid
invest
tuberculosi
research
crosscut
theme
includ
vaccinolog
therapeut
global
health
mrc
top
funder
influenza
european
commiss
top
funder
diagnost
data
avail
global
burden
diseas
dali
correl
level
research
invest
figur
tabl
use
dali
midpoint
studi
timefram
overal
invest
per
dali
respiratori
infect
whole
per
dali
tuberculosi
rel
less
invest
measl
pertussi
diphtheria
rel
invest
respiratori
infecti
diseas
strongli
correl
diseas
burden
dali
spearman
r
pneumonia
arguabl
current
neglect
respiratori
disciplin
term
r
invest
uk
demonstr
rel
greater
invest
influenza
tuberculosi
figur
chang
invest
show
tuberculosi
influenza
pneumonia
receiv
greater
focu
later
time
period
figur
studi
first
systemat
analysi
research
fund
respiratori
infect
research
quantifi
research
fund
preclin
scienc
translat
type
research
rel
littl
amount
spent
phase
clinic
trial
product
develop
studi
half
research
fund
tuberculosi
influenza
vaccin
develop
global
health
studi
form
key
part
uk
research
output
although
proportion
less
global
health
research
within
respiratori
infecti
diseas
across
infecti
diseas
studi
period
increas
influenza
research
fund
limit
fund
emerg
infect
coronavirus
evid
increas
fund
time
although
sum
fund
per
annum
unpredict
declin
sinc
may
reflect
global
econom
condit
tuberculosi
influenza
pneumonia
receiv
increas
invest
compar
may
due
systemat
approach
collect
burden
data
thu
translat
r
invest
focu
influenza
like
least
part
due
highlight
emerg
strain
pandem
potenti
strong
correl
burden
invest
encourag
broadli
highburden
diseas
receiv
greater
fund
pneumonia
key
except
lowerburden
infect
less
fund
within
therapeut
research
proportion
greater
invest
tuberculosi
compar
influenza
seem
appropri
tuberculosisrel
focu
within
diagnost
new
highimpact
infect
threat
human
often
relat
respiratori
system
sar
influenza
middl
east
respiratori
syndrom
potenti
highli
virul
rapid
transmiss
global
spread
substanti
health
econom
impact
although
difficult
accur
quantifi
dataset
littl
fund
research
develop
predict
epidemiolog
model
futur
would
import
part
infect
prevent
control
howev
caution
must
exercis
develop
epidemiolog
model
use
limit
invest
data
collect
predict
model
analysi
health
econom
impact
without
intervent
prioriti
funder
along
invest
preclin
scienc
clinic
trial
lack
invest
coronavirusrel
research
across
type
scienc
particularli
concern
though
surveil
research
respons
outbreak
necessarili
receiv
formal
fund
thu
may
captur
analysi
pseudomona
outbreak
death
neonat
unit
northern
highlight
need
research
prevent
nosocomi
outbreak
relat
respiratori
infecti
diseas
limit
fund
pneumococc
pneumonia
research
infect
mening
may
declin
countri
due
success
introduct
new
still
mani
area
global
weak
health
system
pneumococc
incid
high
also
evid
respiratori
infect
transmiss
mass
gather
addit
provid
meningococc
influenza
vaccin
travel
invest
oper
research
explor
health
system
respons
emerg
threat
effici
way
provid
prevent
medicin
well
measur
effect
prevent
therapi
littl
fund
translat
research
relat
pneumonia
clear
gap
uk
portfolio
vaccineprevent
diseas
measl
pertussi
caus
high
diseas
burden
global
also
receiv
limit
research
fund
despit
clearli
need
translat
oper
worldwid
burden
drugresist
tuberculosi
rapidli
increas
estim
case
multidrugresist
tuberculosi
worldwid
great
variat
countri
emerg
last
decad
extens
drugresist
given
difficulti
develop
effect
need
new
diagnost
therapeut
target
use
exist
medicin
becom
even
import
report
resist
antivir
drug
use
treat
emphasis
need
develop
effect
antivir
effect
vaccin
pauciti
research
antimicrobi
concern
highlight
uk
chief
medic
new
fund
research
relat
antimicrobi
resist
believ
funder
follow
lead
countri
underinvest
tuberculosi
r
requir
addit
invest
drugresist
tuberculosi
contain
differ
top
funder
individu
diseas
pathogen
highlight
import
maintain
access
divers
group
fund
institut
collabor
privat
sector
urgent
requir
vaccin
develop
therapeut
diagnost
evid
public
sector
invest
decreas
privat
new
novel
sourc
invest
possibl
philanthrop
government
bodi
would
help
focu
prioriti
area
particularli
given
reduct
public
fund
coincid
reduct
privat
sector
resourc
sovereign
wealth
fund
belong
individu
nation
could
also
note
consider
incid
ultim
influenc
alloc
resourc
consider
may
includ
preval
predict
impact
diseas
treatabl
diseas
antibiot
cours
combin
differ
pneumonia
tuberculosi
cofactor
comorb
eg
tuberculosi
coinfect
hiv
consider
type
research
may
impact
inform
issu
control
spread
respiratori
infecti
diseas
eg
basic
immunolog
research
may
eventu
inform
futur
vaccin
develop
anticip
futur
new
tool
technolog
research
method
must
also
suppli
line
individu
suffici
skill
motiv
carri
research
studi
sever
limit
highlight
discuss
detail
littl
publicli
avail
data
pharmaceut
industri
henc
data
gap
relat
fund
clinic
trial
develop
vaccin
diagnost
pharmaceut
biotechnolog
industri
financ
beyond
diseas
burden
measur
econom
burden
also
utilis
prioritis
limit
resourc
littl
inform
avail
regard
econom
impact
respiratori
infect
reli
origin
data
complet
accur
unabl
take
account
distribut
fund
lead
institut
collabor
partner
assess
quantiti
award
given
overhead
impact
introduct
fulleconom
cost
also
assign
studi
categori
subject
imperfect
use
two
research
reduc
interobserv
error
studi
focus
ukl
know
whether
similar
pattern
eg
domin
preclin
research
lack
public
charit
fund
clinic
trial
would
also
emerg
analysi
repeat
highincom
countri
measur
either
output
impact
fund
research
assess
measur
burden
use
comprehens
dali
figur
avail
estim
reliabl
precis
known
uk
well
place
contribut
mani
prioriti
research
area
need
addit
fund
given
particular
focus
preclin
scienc
well
oper
implement
research
howev
need
funder
countri
provid
similar
detail
inform
fund
studi
build
global
research
fund
databas
could
use
analyt
work
identifi
gap
research
fund
reduc
unnecessari
duplic
research
invest
prioritis
health
social
polici
decis
help
inform
resourc
alloc
global
research
prioriti
